SOBI: 2025 Revenue, Adj. EBITA Margin Higher Than Prior Guidance

Swedish Orphan Biovitrum (SOBI) reported full-year 2025 revenue of approximately SEK 28.2 billion, about 15% growth at constant exchange rates, and an adjusted EBITA margin near 40% of revenues—both metrics above prior guidance (low double-digit CER growth and mid-to-high‑30s margin). The upside was driven by stronger-than-expected Q4 sales of Doptelet, Gamifant and the haemophilia portfolio, with higher revenue translating into a higher adjusted EBITA margin and improved profitability outlook.

Analysis

Market structure: SOBI (SOBI.ST) is a clear near-term winner — FY2025 revenue SEK 28.2bn (+15% CER) and ~40% adjusted EBITA margin imply strengthening pricing power in niche rare-disease franchises (Doptelet, Gamifant, haemophilia). Competitors with overlapping indications face share loss; payors may push for tighter formulary management in 6–12 months if unit volumes stall. Cross-asset: stronger cash flow reduces credit risk and should modestly tighten SOBI-specific bond spreads; SEK may appreciate on better export receipts if currency translation benefits remain consistent.

Risk assessment: Key tail risks are regulatory setbacks (label changes or new competitor approvals) and demand concentration — estimate 10–20% probability over 12 months that one major product faces adverse news that cuts revenue >10% YoY. Immediate risk (days) is sentiment-driven pullback post-release; short-term (weeks–months) risks include channel-stocking or Q1 revenue normalization; long-term (quarters) risk centers on patent expiry/generic entry and margin sustainability. Hidden dependencies: outcomes hinge on a few product lines — monitor country-level tender renewals and distributor inventory; catalysts include upcoming quarterly updates and any EMA/ FDA filings in next 90 days.

Trade implications: Direct play — establish a 1–3% long in SOBI.ST sized to portfolio volatility, targeting 12–18% absolute upside over 3–12 months if growth persists; add on pullbacks >10%. Pair trade — long SOBI.ST vs short Grifols (GRFSY) 0.8–1x exposure to express idiosyncratic outperformance given plasma-price pressure on Grifols. Options — buy 3–6 month call spreads (15–25%/30–40% OTM) to cap downside and leverage upside; size as 0.5–1% equity equivalents.

Contrarian angles: Consensus may underweight sustainability of a 40% EBITA margin — if driven by scale rather than one-offs, SOBI could re-rate; conversely, market may be complacent about concentration risk. Historical parallels: companies that re-rated on commercial execution (mid-2010s specialty biotech) later reversed when one product faltered — set hard stop-loss rules. Unintended consequence: aggressive long sizing without monitoring quarterly product-level disclosures risks >25% drawdown if Doptelet or Gamifant revenues decline materially.

Key Decisions for Investors

• Establish a 1.5–3.0% long position in Swedish Orphan Biovitrum (SOBI.ST) within 1–2 trading days, target a 12–18% return within 3–12 months; add up to +1% on any pullback >10% from entry and trim if adjusted EBITA margin falls below 36% or FY revenue growth guidance drops under 8% YoY.
• Implement a relative-value pair: long SOBI.ST (1.0x) vs short Grifols ADR (GRFSY) (0.8x) sized to net-neutral beta exposure, horizon 3–9 months; rationale: SOBI benefits from high-margin specialty launches while Grifols faces plasma pricing and margin pressure.
• Buy 3–6 month call spread on SOBI.ST sized to 0.5–1.0% portfolio risk: long 15–25% OTM calls and short 30–40% OTM calls to capture upside while limiting premium; roll or unwind if implied volatility doubles or if next quarterly product-level sales miss consensus by >5%.
• Reduce or avoid new exposure to broad European small-cap biotech ETFs if they lack exposure to high-margin commercial franchises; reallocate 2–4% of that allocation into SOBI.ST and 1% into cash until next quarter disclosures (next 60–90 days) confirm product-level durability.